Annals of Surgical Oncology

, Volume 10, Issue 9, pp 1054–1058 | Cite as

Outcomes After Localized Axillary Node Recurrence in Breast Cancer

  • F. C. Wright
  • J. Walker
  • C. H. L. Law
  • D. R. McCready
Original Articles


Background: Localized axillary recurrence (LAR) is an uncommon event. It is estimated to occur in 0.5% to 3% of patients when adequate axillary surgery has been performed. Although relatively sparse data exist on the outcome of patients with LAR, in the era of sentinel node biopsy (SNB) these data may have increased relevance. This study assesses the survival outcomes in these patients.

Methods: A retrospective chart review was completed. Patient age, tumor size, pathology, receptor status, and treatment of the primary breast carcinoma were reviewed. Axillary recurrence, treatment, and overall survival data were collected.

Results: Fifteen patients were identified with LAR that developed at a median of 77 months after their initial dissection. At the time of treatment for their LAR, all patients had completion axillary clearance and six also had a concurrent completion mastectomy. Further adjuvant treatment was individualized. Five patients (33%) have died, including all patients (3) who developed a LAR within 2 years of their initial breast cancer presentation. Ten-year overall survival is 56%.

Conclusion: Our experience suggests early (<24 months) LAR is indicative of a poor prognosis. With multimodal treatment, ten-year overall survival is 56%.

Key Words

Breast cancer Axillary recurrence Survival Surgery 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Touboul E, Buffat L, Belkacemi Y, et al. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 1999;43:25–38.PubMedGoogle Scholar
  2. 2.
    Clemons M, Hamilton T, Goss P. Does treatment at the time of locoregional failure of breast cancer alter prognosis? Cancer Treat Rev 2001;27:83–97.PubMedCrossRefGoogle Scholar
  3. 3.
    Clemons M, Danson S, Hamilton T, Goss P. Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev 2001;27:67–82.PubMedCrossRefGoogle Scholar
  4. 4.
    de Boer R, Hillen HF, Roumen RM, et al. Detection, treatment and outcome of axillary recurrence after axillary clearance for invasive breast cancer. Br J Surg 2001;88:118–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med 1998;339:941–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001;233:51–9.PubMedCrossRefGoogle Scholar
  7. 7.
    McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000;18:2560–6.PubMedGoogle Scholar
  8. 8.
    Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999;84:138–42.PubMedCrossRefGoogle Scholar
  9. 9.
    Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer 2002;94:2542–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Lucci A Jr, Kelemen PR, Miller C III, Chardkoff L, Wilson L. National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg 2001;192:453–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Petrasek AJ, Semple JL, McCready DR. The surgical and oncologic significance of the axillary arch during axillary lymphadenectomy. Can J Surg 1997;40:44–7.PubMedGoogle Scholar
  12. 12.
    Renolleau C, Merviel P, Clough KB, et al. Isolated axillary recurrences after conservative treatment of breast cancer. Eur J Cancer 1996;32A:617–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Halverson KJ, Taylor ME, Perez CA, et al. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 1993;26:593–9.PubMedGoogle Scholar
  14. 14.
    Halverson KJ, Perez CA, Kuske RR, et al. Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1992;23:285–91.PubMedGoogle Scholar
  15. 15.
    Fowble B, Solin LJ, Schultz DJ, Goodman RL. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys 1989;17:703–10.PubMedGoogle Scholar
  16. 16.
    Willner J, Kiricuta IC, Kolbl O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1997;37:853–63.PubMedGoogle Scholar
  17. 17.
    Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988;14:407–12.PubMedGoogle Scholar
  18. 18.
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674–81.PubMedCrossRefGoogle Scholar
  19. 19.
    McKinna F, Gothard L, Ashley S, Ebbs SR, Yarnold JR. Lymphatic relapse in women with early breast cancer: a difficult management problem. Eur J Cancer 1999;35:1065–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Weir L, Speers C, D’yachkova Y, Olivotto IA. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol 2002;20:1793–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:1415–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol 1998;5:140–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Newman LA, Hunt KK, Buchholz T, et al. Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg 2000;180:252–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Guenther JM, Hansen NM, DiFronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg 2003;138:52–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Clemente CD. Anatomy of the human body. Gray’s Anatomy, 13th ed. Philadelphia: Lea & Febiger, 1985:515.Google Scholar
  27. 27.
    Serpell JW, Baum M. Significance of ’Langer’s axillary arch’ in axillary dissection. Aust N Z J Surg 1991;61:310–2.PubMedCrossRefGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  • F. C. Wright
    • 1
  • J. Walker
    • 1
  • C. H. L. Law
    • 1
  • D. R. McCready
    • 1
    • 2
  1. 1.Department of SurgeryUniversity of TorontoTorontoCanada
  2. 2.Department of Surgical OncologyPrincess Margaret Hospital, University of TorontoTorontoCanada

Personalised recommendations